Parkinson's disease

BR Bloem, MS Okun, C Klein - The Lancet, 2021 - thelancet.com
Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical
presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; …

[HTML][HTML] Parkinson disease-associated cognitive impairment

D Aarsland, L Batzu, GM Halliday… - Nature Reviews …, 2021 - nature.com
Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Genetics and pathogenesis of Parkinson's syndrome

H Ye, LA Robak, M Yu, M Cykowski… - Annual Review of …, 2023 - annualreviews.org
Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous,
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …

TRP (transient receptor potential) ion channel family: Structures, biological functions and therapeutic interventions for diseases

M Zhang, Y Ma, X Ye, N Zhang, L Pan… - Signal Transduction and …, 2023 - nature.com
Transient receptor potential (TRP) channels are sensors for a variety of cellular and
environmental signals. Mammals express a total of 28 different TRP channel proteins, which …

Detection of neuron-derived pathological α-synuclein in blood

A Kluge, J Bunk, E Schaeffer, A Drobny, W **ang… - Brain, 2022 - academic.oup.com
To date, no reliable clinically applicable biomarker has been established for Parkinson's
disease. Our results indicate that a long anticipated blood test for Parkinson's disease may …

Periphery and brain, innate and adaptive immunity in Parkinson's disease

AS Harms, SA Ferreira, M Romero-Ramos - Acta neuropathologica, 2021 - Springer
Parkinson's disease (PD) is a neurodegenerative disorder where alpha-synuclein plays a
central role in the death and dysfunction of neurons, both, in central, as well as in the …

The gut–brain axis and its relation to Parkinson's disease: a review

EM Klann, U Dissanayake, A Gurrala… - Frontiers in aging …, 2022 - frontiersin.org
Parkinson's disease is a chronic neurodegenerative disease characterized by the
accumulation of misfolded alpha-synuclein protein (Lewy bodies) in dopaminergic neurons …

Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease

LMA Oliveira, T Gasser, R Edwards… - npj Parkinson's …, 2021 - nature.com
With the advent of the genetic era in Parkinson's disease (PD) research in 1997, α-synuclein
was identified as an important player in a complex neurodegenerative disease that affects> …

Neuroimaging and fluid biomarkers in Parkinson's disease in an era of targeted interventions

A Zarkali, GEC Thomas, H Zetterberg… - Nature …, 2024 - nature.com
A major challenge in Parkinson's disease is the variability in symptoms and rates of
progression, underpinned by heterogeneity of pathological processes. Biomarkers are …

Alpha-synuclein as a biomarker of Parkinson's disease: good, but not good enough

U Ganguly, S Singh, S Pal, S Prasad… - Frontiers in aging …, 2021 - frontiersin.org
Parkinson's disease (PD) is the second most common neurodegenerative disorder of the
elderly, presenting primarily with symptoms of motor impairment. The disease is diagnosed …